236 related articles for article (PubMed ID: 28986919)
1. Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood.
Schwarz C; Müller T; Lau S; Parasher K; Staab D; Wahn U
Pediatr Allergy Immunol; 2018 Feb; 29(1):28-33. PubMed ID: 28986919
[TBL] [Abstract][Full Text] [Related]
2. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome.
Kuang FL; Fay MP; Ware J; Wetzler L; Holland-Thomas N; Brown T; Ortega H; Steinfeld J; Khoury P; Klion AD
J Allergy Clin Immunol Pract; 2018; 6(5):1518-1527.e5. PubMed ID: 29751154
[TBL] [Abstract][Full Text] [Related]
5. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
6. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
Schwartz LB; Sheikh J; Singh A
Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
[TBL] [Abstract][Full Text] [Related]
7. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
Roufosse F; Kahn JE; Rothenberg ME; Wardlaw AJ; Klion AD; Kirby SY; Gilson MJ; Bentley JH; Bradford ES; Yancey SW; Steinfeld J; Gleich GJ;
J Allergy Clin Immunol; 2020 Dec; 146(6):1397-1405. PubMed ID: 32956756
[TBL] [Abstract][Full Text] [Related]
9. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome.
Roufosse F; de Lavareille A; Schandené L; Cogan E; Georgelas A; Wagner L; Xi L; Raffeld M; Goldman M; Gleich GJ; Klion A
J Allergy Clin Immunol; 2010 Oct; 126(4):828-835.e3. PubMed ID: 20810155
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
Roufosse FE; Kahn JE; Gleich GJ; Schwartz LB; Singh AD; Rosenwasser LJ; Denburg JA; Ring J; Rothenberg ME; Sheikh J; Haig AE; Mallett SA; Templeton DN; Ortega HG; Klion AD
J Allergy Clin Immunol; 2013 Feb; 131(2):461-7.e1-5. PubMed ID: 23040887
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5.
Rothenberg ME; Roufosse F; Faguer S; Gleich GJ; Steinfeld J; Yancey SW; Mavropoulou E; Kwon N;
J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2367-2374.e3. PubMed ID: 35568330
[TBL] [Abstract][Full Text] [Related]
13. [Use of mepolizumab in hypereosinophilic syndromes: The position and proposals of the national reference center for hypereosinophilic syndromes].
Kahn JE; Lefèvre G; Groh M
Rev Med Interne; 2023 Apr; 44(4):155-157. PubMed ID: 36997273
[No Abstract] [Full Text] [Related]
14. Hypereosinophilic syndrome presenting as an unusual triad of eosinophilia, severe thrombocytopenia, and diffuse arterial thromboses, with good response to mepolizumab.
Leon-Ferre RA; Weiler CR; Halfdanarson TR
Clin Adv Hematol Oncol; 2013 May; 11(5):317-9. PubMed ID: 23880717
[No Abstract] [Full Text] [Related]
15. Hypereosinophilic syndrome and mepolizumab.
Boucher RM; Gilbert-McClain L; Chowdhury B
N Engl J Med; 2008 Jun; 358(26):2838-9; author reply 2839-40. PubMed ID: 18579821
[No Abstract] [Full Text] [Related]
16. Familial clustering of hypereosinophilic diseases treated with mepolizumab: a case report from Japan.
Kurosawa M; Sutoh Y; Sutoh E
Eur Ann Allergy Clin Immunol; 2020 Jan; 52(1):39-44. PubMed ID: 31594295
[TBL] [Abstract][Full Text] [Related]
17. The spectrum of therapeutic activity of mepolizumab.
Cavaliere C; Frati F; Ridolo E; Greco A; de Vincentiis M; Masieri S; Makri E; Incorvaia C
Expert Rev Clin Immunol; 2019 Sep; 15(9):959-967. PubMed ID: 31424304
[No Abstract] [Full Text] [Related]
18. Efficacy and Safety of Mepolizumab (Anti-Interleukin-5) Treatment in Gleich's Syndrome.
Matucci A; Liotta F; Vivarelli E; Dies L; Annunziato F; Piccinni MP; Nencini F; Pratesi S; Maggi E; Vultaggio A
Front Immunol; 2018; 9():1198. PubMed ID: 29896203
[TBL] [Abstract][Full Text] [Related]
19. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
20. Hypereosinophilic syndrome and mepolizumab.
Verzegnassi F
N Engl J Med; 2008 Jun; 358(26):2838; author reply 2839-40. PubMed ID: 18584819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
